Clinical Trial Update: Study of Karenitecin (BNP1350) in Patients With Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 study of Karenitecin (BNP1350) in patients with brain tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Brain Tumors
• Malignant Neoplasms Brain

Drugs mentioned

• Karenitecin

Snippet

Sponsor: BioNumerik Pharmaceuticals, Inc. | Conditions: Brain Neoplasms, Malignant Neoplasms, Brain | Phase 2 | Status: COMPLETED